Quest Laboratories Ltd
Founded in June 1998, Quest Laboratories Limited produces a diverse range of pharmaceuticals, including antibiotics, antimalarials, anti-inflammatories, etc.[1]
- Market Cap ₹ 233 Cr.
- Current Price ₹ 142
- High / Low ₹ 197 / 85.1
- Stock P/E 19.8
- Book Value ₹ 48.7
- Dividend Yield 0.00 %
- ROCE 57.5 %
- ROE 46.1 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 45.5%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 46.3 days to 73.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 84 | |
| 29 | 53 | 54 | 67 | 67 | |
| Operating Profit | 1 | 6 | 8 | 16 | 18 |
| OPM % | 5% | 11% | 13% | 19% | 21% |
| 0 | 0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 17 |
| Tax % | 18% | 29% | 28% | 30% | |
| 1 | 4 | 5 | 10 | 12 | |
| EPS in Rs | 8.45 | 8.05 | |||
| Dividend Payout % | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 40% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 148% |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 45% |
| Last Year: | 46% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 63 |
| 3 | 3 | 4 | 5 | 10 | |
| 9 | 22 | 28 | 26 | 23 | |
| Total Liabilities | 18 | 35 | 47 | 59 | 113 |
| 6 | 7 | 10 | 10 | 11 | |
| CWIP | -0 | -0 | -0 | -0 | -0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 12 | 27 | 37 | 49 | 101 | |
| Total Assets | 18 | 35 | 47 | 59 | 113 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 1 | 3 | 4 | 3 | |
| -1 | -2 | -4 | -5 | |
| 0 | -0 | -0 | 2 | |
| Net Cash Flow | -0 | 1 | 0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 104 |
| Inventory Days | 12 | 9 | 97 | 113 |
| Days Payable | 119 | 140 | 215 | 137 |
| Cash Conversion Cycle | 3 | 4 | 1 | 79 |
| Working Capital Days | 31 | 25 | 40 | 74 |
| ROCE % | 55% | 47% | 58% |
Documents
Announcements
-
Integrated Filing- Governance
29 January 2025 - Submission of Statement of Investor Grievance & Redressal Mechanism under Regulation 13(3) of the SEBI (LODR) Regulations, 2015 for the quarter ended on 31st December, …
-
Outcome of Board Meeting
27 January 2025 - Quest Laboratories Limited has informed regarding Outcome of Board Meeting held on January 27, 2025.
-
Analysts/Institutional Investor Meet/Con. Call Updates
24 January 2025 - Quest Laboratories Limited has informed about OUTCOME
-
Updates
17 January 2025 - Quest Laboratories Limited has informed regarding 'Mr. Vinayak Sabarwal has acquired 2400 Equity Shares representing 0.015% of the paid-up equity share capital of Quest Laboratories …
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
16 January 2025 - Quest Laboratories Limited has informed about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Annual reports
Concalls
-
Dec 2024TranscriptNotesPPT
Product Profile[1] The company produces ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids.